Form 4: Lemaitre Vascular Director Reports Routine Acquisition of Dividend Equivalent Rights

Lemaitre Vascular Inc. Director Lawrence J. Jasinski reported the acquisition of dividend equivalent rights tied to his restricted and performance stock unit awards on May 29, 2025, as part of his ongoing compensation.

Summary

• Lawrence J. Jasinski, a Director of Lemaitre Vascular Inc. (LMAT), filed a Form 4 reporting changes in beneficial ownership.
• The filing details the acquisition of Dividend Equivalent Rights (DERs) on May 29, 2025.
• These DERs are the economic equivalent of one share of the Issuer's common stock and accrued on previously granted restricted stock unit (RSU) and performance stock unit (PSU) awards.
• The acquired DERs include 0.4985 units related to an RSU award granted on December 12, 2022, and 0.4985 units related to a PSU award granted on the same date.
• Additional DERs acquired include 0.8524 units from an RSU award granted on December 8, 2023, and 1.0208 units from a PSU award granted on the same date.
• Furthermore, 1.0387 units were acquired from an RSU award granted on December 6, 2024.
• All these dividend equivalent rights vest proportionately with their respective underlying RSU and PSU awards.
• The reported price for these acquisitions was $0, as they represent accrued dividend equivalents rather than direct share purchases.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. This is a routine insider compensation report, indicating ongoing alignment of director interests with shareholders through equity awards. It does not suggest any immediate positive or negative operational or financial news for the company.

Positives

• The acquisition of Dividend Equivalent Rights (DERs) aligns the director's financial interests with those of common shareholders, as the value of these rights is tied to the company's common stock and dividend payments.
• This transaction is part of a standard, ongoing equity compensation plan for the director, indicating stability in executive compensation structure.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports a past insider transaction related to compensation.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reporting changes in beneficial ownership by insiders. The use of Dividend Equivalent Rights (DERs) tied to Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) is a common practice in executive and director compensation across various industries, particularly in the medical device sector where Lemaitre Vascular operates. This structure aims to align the interests of company leadership with long-term shareholder value creation, as DERs accrue based on dividends paid on underlying equity awards.

Comparison to Industry Standards

• The use of Dividend Equivalent Rights (DERs) as part of equity compensation for directors is a common practice among publicly traded companies, including those in the medical device industry like Medtronic, Boston Scientific, or Edwards Lifesciences, although specific structures and grant sizes vary.
• DERs, particularly when tied to performance-based awards (PSUs), are considered a best practice in corporate governance as they incentivize long-term value creation and align director interests with shareholder returns, similar to compensation models seen in other mature companies.

Related Party Transactions

• The reported transaction involves the acquisition of dividend equivalent rights by a director of Lemaitre Vascular Inc., which is a standard related-party transaction concerning executive compensation.

Stakeholder Impact

• Shareholders: The acquisition of dividend equivalent rights by a director generally has a minor positive impact as it further aligns the director's financial interests with those of the shareholders, particularly regarding dividend payouts and long-term stock performance.

Key Dates

Recommendation

Keywords

Lemaitre Vascular, LMAT, SEC Form 4, Insider Transaction, Beneficial Ownership, Dividend Equivalent Rights, Restricted Stock Units, Performance Stock Units, Director Compensation, Equity Compensation